# CheckMate 227 (NCT02477826)

> An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02477826
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Nivolumab; Ipilimumab; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed; Paclitaxel
- Enrollment: 2747
- Primary outcome: Progression-Free Survival Per BICR
- Primary outcome: Overall Survival

## Commentary we found

- YouTube: 40
- Podcasts: 36
- X threads: 26

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-227-nct02477826

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02477826", "email": "<work email>"}; the inbox owner confirms by the emailed link.